Disruptive biotech companies developing cell and gene therapies (CGT) and other precision medicines remain imperative for industry evolution, and specifically, Contract Development Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) will play a critical role in the coming years.

It wasn’t long ago when the term “artificial intelligence” (AI) conjured up images of hyper realistic human robots or flying cars.

With JPM 2022 having finished up last week, new standout partnerships between promising biotech companies and profitable big pharma show that reciprocity between players…

Demographically, South Korea has been an appealing investment opportunity for pharma companies. It has a relatively large population of around 51 million people…

The growing biopharmaceutical market in China has become increasingly appealing to international entrepreneurs and investors, with recent…

Discussion in biotech often focuses on new therapeutics and technologies being developed that have the potential to cure cancer and rare genetic diseases…